- Home
- MAGN vs BCYC Comparison
MAGN vs BCYC Comparison
Compare MAGN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGN
- BCYC
- Stock Information
- Founded
- MAGN 1864
- BCYC 2009
- Country
- MAGN United States
- BCYC United Kingdom
- Employees
- MAGN N/A
- BCYC N/A
- Industry
- MAGN Paper
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- MAGN Basic Materials
- BCYC Health Care
- Exchange
- MAGN Nasdaq
- BCYC Nasdaq
- Market Cap
- MAGN 473.5M
- BCYC 566.5M
- IPO Year
- MAGN N/A
- BCYC 2019
- Fundamental
- Price
- MAGN $11.87
- BCYC $7.99
- Analyst Decision
- MAGN Hold
- BCYC Buy
- Analyst Count
- MAGN 1
- BCYC 11
- Target Price
- MAGN $14.00
- BCYC $25.00
- AVG Volume (30 Days)
- MAGN 679.0K
- BCYC 277.2K
- Earning Date
- MAGN 08-06-2025
- BCYC 08-12-2025
- Dividend Yield
- MAGN N/A
- BCYC N/A
- EPS Growth
- MAGN N/A
- BCYC N/A
- EPS
- MAGN N/A
- BCYC N/A
- Revenue
- MAGN $2,636,000,000.00
- BCYC $25,722,000.00
- Revenue This Year
- MAGN $47.87
- BCYC $7.35
- Revenue Next Year
- MAGN $4.76
- BCYC N/A
- P/E Ratio
- MAGN N/A
- BCYC N/A
- Revenue Growth
- MAGN 15.87
- BCYC N/A
- 52 Week Low
- MAGN $11.43
- BCYC $6.10
- 52 Week High
- MAGN $26.78
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- MAGN N/A
- BCYC 46.46
- Support Level
- MAGN N/A
- BCYC $8.40
- Resistance Level
- MAGN N/A
- BCYC $8.88
- Average True Range (ATR)
- MAGN 0.00
- BCYC 0.50
- MACD
- MAGN 0.00
- BCYC -0.00
- Stochastic Oscillator
- MAGN 0.00
- BCYC 24.40
About MAGN Magnera Corporation Common Stock
Magnera Corp formerly Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company's reportable segments are; Composite Fibers, Spunlace. and Airlaid Materials. The Airlaid Materials segment which is also its key revenue generating segment, is a supplier of cellulose-based airlaid nonwoven materials used to manufacture consumer products for end-user markets. The Airlaid Materials segment produces materials used in feminine hygiene, specialty wipes, tabletop, home care, and other consumables. Geographically, the company derives majority of its revenue from Americas and rest from Europe, Middle East, Africa and Asia Pacific markets.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.